These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 3455805

  • 1. [A case of complete remission from acute myelogenous leukemia in second relapse achieved using an intermediate-dose cytosine arabinoside (ID Ara-C) regimen].
    Yoshida M, Owada N, Sasaki R, Sakamoto S, Miura Y.
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):143-6. PubMed ID: 3455805
    [Abstract] [Full Text] [Related]

  • 2. [Clinical effect and pharmacokinetics of intermediate dose Ara-C therapy in a patient with acute non-lymphocytic leukemia with two CNS recurrences].
    Fukushima T, Ueda T, Kamiya K, Yoshida W, Tsutani H, Uchida M, Nakamura T, Kagawa D, Domae N.
    Nihon Gan Chiryo Gakkai Shi; 1990 Jan 20; 25(1):126-31. PubMed ID: 2324584
    [Abstract] [Full Text] [Related]

  • 3. [Therapeutic effects of a combination of intermediate-dose cytosine arabinoside, adriamycin and vincristine in relapsed acute leukemia].
    Takahashi I, Yorimitsu S, Inagaki T, Sekito N, Hayashi N, Nishimura M, Aoyama S, Nakada H, Ohmoto E, Uchida K.
    Gan To Kagaku Ryoho; 1987 Feb 20; 14(2):485-9. PubMed ID: 3813576
    [Abstract] [Full Text] [Related]

  • 4. [High dosage and intermediate dosage cytosine arabinoside in the treatment of secondary leukemias].
    Leitha T, Jäger U, Schwarzinger I, Bettelheim P, Hinterberger W, Neumann E, Korninger C, Kyrle PA, Haas O, Schlappack O.
    Wien Klin Wochenschr; 1988 Aug 05; 100(15):509-14. PubMed ID: 3176503
    [Abstract] [Full Text] [Related]

  • 5. [Treatment of a case of childhood acute non-lymphocytic leukemia (ANLL) using high-dose cytosine arabinoside for intensification of early therapy].
    Imashuku S, Nakajima T, Morimoto S, Hibi S, Todo S, Morioka Y, Sugimoto T.
    Gan To Kagaku Ryoho; 1987 Feb 05; 14(2):527-30. PubMed ID: 3813580
    [Abstract] [Full Text] [Related]

  • 6. [Refractory acute myelogenous leukemia successfully treated with a continuous infusion chemotherapy of low dose aclarubicin and cytosine arabinoside: a case report].
    Kawada H, Komatsuda M, Masumoto A, Fukuda R, Watanabe S, Yonekura S, Ichikawa Y, Nagao T, Arimori S.
    Rinsho Ketsueki; 1993 May 05; 34(5):667-9. PubMed ID: 8315839
    [Abstract] [Full Text] [Related]

  • 7. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
    Meng FY, Yang LJ, Xu B, Liu XL, Zheng WY, Zhang Y, Huang F, Sun J, Liu QF.
    Ai Zheng; 2003 Dec 05; 22(12):1330-3. PubMed ID: 14693062
    [Abstract] [Full Text] [Related]

  • 8. [Low-dose 4N-behenoyl-1-beta-D-arabinofuranosylcytosine (BHAC) in the treatment of atypical leukemia].
    Takahashi I, Nakada H, Hayashi N, Sekito N, Inagaki T, Aoyama S, Nonaka K, Ohmoto E, Kobayashi Y, Uchida K.
    Gan To Kagaku Ryoho; 1986 Sep 05; 13(9):2780-5. PubMed ID: 3463249
    [Abstract] [Full Text] [Related]

  • 9. High-dose cytosine arabinoside as consolidation chemotherapy for acute nonlymphocytic leukemia in remission.
    Urabe A, Mizoguchi H, Hoshino S, Nomura T, Dan K, Toyama K, Kimura M, Ogawa T, Yamaguchi H, Mutoh Y.
    Int J Hematol; 1991 Feb 05; 54(1):75-7. PubMed ID: 1954354
    [Abstract] [Full Text] [Related]

  • 10. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
    Early AP, Preisler HD, Slocum H, Rustum YM.
    Cancer Res; 1982 Apr 05; 42(4):1587-94. PubMed ID: 6949642
    [Abstract] [Full Text] [Related]

  • 11. [High doses of cytosine arabinoside in the treatment of patients with acute relapsing or refractory leukemia].
    Lobato-Mendizábal E, Ruiz-Argüelles GJ, Marín-López A.
    Rev Invest Clin; 1989 Apr 05; 41(2):139-45. PubMed ID: 2675236
    [Abstract] [Full Text] [Related]

  • 12. [The use of intermediate dose cytosine arabinoside (ID Ara-C) in the treatment of relapsing or refractory cases of acute myelogenous leukemia].
    Kawano F, Tejima Y, Tajima H, Lee SY, Shiozaki A, Nakai R, Chyosa M, Sawada T, Maeda Y, Mizokuni T.
    Rinsho Ketsueki; 1986 Mar 05; 27(3):315-20. PubMed ID: 3461178
    [No Abstract] [Full Text] [Related]

  • 13. [Intermittent-dose ara-C/daunomycin therapy combined with cyclosporin-A and G-CSF led to a fourth remission in a patient with acute promyelocytic leukemia].
    Motomura S, Fujisawa S, Anzai S, Fujimaki K, Hattori M, Fukawa H, Okubo T.
    Rinsho Ketsueki; 1995 Aug 05; 36(8):762-7. PubMed ID: 7563610
    [Abstract] [Full Text] [Related]

  • 14. [Cytosine-arabinoside in high doses in refractory acute granulocytic leukemia. Apropos of 17 cases].
    Jouet JP, Simon M, Fenaux P, Pollet JP, Bauters F.
    Nouv Rev Fr Hematol (1978); 1985 Aug 05; 27(3):169-73. PubMed ID: 3862072
    [Abstract] [Full Text] [Related]

  • 15. Induction therapy of newly diagnosed acute nonlymphocytic leukemia with idarubicin and cytosine arabinoside--the Taiwan experience.
    Chen YC, Lin SF, Yao M, Chen TY, Tsao CJ, Chen TP.
    Semin Hematol; 1996 Oct 05; 33(4 Suppl 3):30-4. PubMed ID: 8916314
    [Abstract] [Full Text] [Related]

  • 16. [Low dose continuous infusion therapy with etoposide (VP-16) and cytosine arabinoside (Ara-C) for a patient with refractory acute myelogenous leukemia].
    Koyama S, Itou S, Shibata A.
    Rinsho Ketsueki; 1990 Nov 05; 31(11):1891-2. PubMed ID: 2287079
    [Abstract] [Full Text] [Related]

  • 17. Mitoxantrone and ara-C in previously treated patients with acute myelogenous leukemia.
    Paciucci PA, Dutcher JP, Cuttner J, Strauman JJ, Wiernik PH, Holland JF.
    Leukemia; 1987 Jul 05; 1(7):565-7. PubMed ID: 3478540
    [Abstract] [Full Text] [Related]

  • 18. [Intermediate- and high-dose cytosine arabinoside therapy in acute refractory leukemia].
    Ohshima A, Yoshida K, Sato T, Miyazaki S, Yanagisawa M, Nakayama Y, Takahashi T, Mamiya S, Fukusima Y, Miura AB.
    Gan To Kagaku Ryoho; 1987 Jan 05; 14(1):192-5. PubMed ID: 3800405
    [Abstract] [Full Text] [Related]

  • 19. [Five cases of de novo acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) achieved CR with the continuous drip infusion of low-dose etoposide and low-dose cytosine arabinoside combined with mitoxantrone (MEtA)].
    Tsukaguchi M, Furukawa Y, Shibano M, Kitani T.
    Gan To Kagaku Ryoho; 2004 Jul 05; 31(7):1119-23. PubMed ID: 15272598
    [Abstract] [Full Text] [Related]

  • 20. [High-dose cytosine arabinoside treatment of leukemia with special reference to the optimal number of doses].
    Sampi K, Maseki N, Kumai R, Kaneko Y, Sakurai M, Hattori M.
    Gan To Kagaku Ryoho; 1989 Aug 05; 16(8 Pt 1):2595-8. PubMed ID: 2774589
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.